文献速递消化道肿瘤放疗放疗物理与技术

放射性淋巴细胞减少是食管癌放化疗后生存的因果中介因素

Radiation-Induced Lymphopenia is a Causal Mediator of Survival After Chemoradiation Therapy for Esophagus Cancer.
PubMed 文献 · Adv Radiat Oncol · 2024-07-26

该回顾性研究纳入2004至2017年734例经活检证实的食管癌同步放化疗患者,采用倾向性评分分析比较质子束治疗与调强放疗,并用因果中介分析分解总效应。质子束治疗与更低的4级放射性淋巴细胞减少发生率和更长的总生存相关,4级放射性淋巴细胞减少介导了约14.5%的总生存差异,但质子束治疗对生存的直接效应未达统计学显著。

要点

  • 质子束治疗较调强放疗显著降低4级放射性淋巴细胞减少发生率(OR 0.41,95%CI 0.28-0.60,P<.001)。
  • 在506例倾向性匹配队列中,质子束治疗较调强放疗的相对死亡风险降低5%(P=.032)。
  • 4级放射性淋巴细胞减少介导了约14.5%的总生存差异,质子束治疗对生存的直接效应未达统计学显著。

核心结论

  • 4级放射性淋巴细胞减少被发介导生存,但质子束治疗对生存的统计学显著直接效应未观察到。
  • 换言之,在该食管癌队列中,质子相对光子的生存获益在缺乏4级放射性淋巴细胞减少风险降低时失去统计学显著性。

研究设计与样本

  • 回顾性评估2004至2017年734例经活检证实的食管癌接受同步放化疗的患者。
  • 采用倾向性评分分析评估并减少质子束治疗与调强放疗队列间的选择偏倚。
  • 应用因果中介分析将放疗方式对总生存的总效应分解为间接效应(经4级放射性淋巴细胞减少介导)和直接效应。

主要发现

  • 质子束治疗与显著更低的4级放射性淋巴细胞减少发生率和延长的总生存相关(OR 0.41,95%CI 0.28-0.60,P<.001)。
  • 在506例倾向性匹配队列(质子束治疗253例,调强放疗253例)中,质子束治疗较调强放疗的4级放射性淋巴细胞减少风险降低转化为相对死亡风险降低5%(P=.032)。
  • 4级放射性淋巴细胞减少介导了总生存差异的约14.5%。

关键数值与推荐

  • 质子束治疗较调强放疗的4级放射性淋巴细胞减少OR为0.41(95%CI 0.28-0.60,P<.001)。
  • 倾向性匹配队列中质子束治疗较调强放疗的相对死亡风险降低5%(P=.032)。
  • 4级放射性淋巴细胞减少介导总生存差异的比例约为14.5%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Radiation-induced lymphopenia (RIL) is common during chemoradiation therapy. Severe lymphopenia is associated with reduced survival. Proton beam therapy (PBT), with its substantially more compact dose distributions, spares circulating lymphocytes and immune organs at risk to a greater extent than photon therapy. Recent studies comparing PBT to photon radiation therapy, specifically intensity-modulated radiation therapy (IMRT) for esophageal cancer (EC), showed that the incidence of grade 4 RIL (G4RIL) is significantly reduced among patients receiving PBT for EC. However, whether the extent of this reduction has a direct causative link with improved survival is unknown. This study applies causal mediation analysis to answer this question. METHODS AND MATERIALS: We retrospectively assessed 734 patients treated with concurrent chemoradiation therapy for biopsy-proven EC from 2004 to 2017. To address the potential for bias in the choice of radiation modality, propensity score analysis was used to evaluate and reduce imbalances between the PBT and IMRT cohorts. Causal mediation analysis was applied to decompose the total effect of radiation modality on overall survival (OS) into indirect (mediated through G4RIL) and direct effects. RESULTS: We found that PBT was associated with a significantly lower incidence of G4RIL and prolonged OS compared with IMRT (odds ratio, 0.41; 95% CI, 0.28-0.60; P < .001). In the propensity-matched cohort of 506 patients (253 PBT, 253 IMRT), G4RIL risk reduction with PBT versus IMRT translated into a 5% reduction in the relative rate of death (P = .032). Mediation of G4RIL explained ∼14.5% of the difference in OS. CONCLUSIONS: G4RIL was found to mediate survival; however, a statistically significant direct effect of PBT on survival was not observed. In other words, the statistical significance of survival benefit from protons over photons in this EC cohort was lost in the absence of G4RIL risk reduction.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Chen Y, Chu Y, van Rossum PSN, et al. Radiation-Induced Lymphopenia is a Causal Mediator of Survival After Chemoradiation Therapy for Esophagus Cancer. Adv Radiat Oncol. 2024. PMID: 39258141. doi:10.1016/j.adro.2024.101579

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。